New light on polyglutamine neurodegenerative disorders: interference with transcription

By Neri C.  

Trends in Molecular Medicine, Vol. 7, Iss. 7, 2001-07 ,pp. : 283-284

Elsevier

Access to resources Recommend Favorite

The transcription repressor, ZEB1, cooperates with CtBP2 and HDAC1 to suppress IL-2 gene activation in T cells

By Wang Jun   Lee Seungsoo   Teh Charis En-Yi   Bunting Karen   Ma Lina   Shannon M. Frances  

International Immunology, Vol. 21, Iss. 3, 2009-03 ,pp. : 227-235

Oxford University Press

Access to resources Recommend Favorite

The role of chaperones in polyglutamine disease

By Opal P.   Zoghbi H.Y.  

Trends in Molecular Medicine, Vol. 8, Iss. 5, 2002-05 ,pp. : 232-236

Elsevier

Access to resources Recommend Favorite

Molecular Genetics and Biomarkers of Polyglutamine Diseases

By  

Current Molecular Medicine, Vol. 8, Iss. 3, 2008-05 ,pp. : 221-234

Bentham Science Publishers

Access to resources Recommend Favorite

Altered acetylation in polyglutamine disease: an opportunity for therapeutic intervention?

By Taylor J.P.   Fischbeck K.H.  

Trends in Molecular Medicine, Vol. 8, Iss. 5, 2002-05 ,pp. : 195-197

Elsevier

Access to resources Recommend Favorite